<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/19/fluidigm-co-nasdaqfldm-sees-large-drop-in-short-interest.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-19T10:26:00+00:00"/>
    <meta property="og:title" content="Fluidigm Co. (NASDAQ:FLDM) Sees Large Drop in Short Interest"/>
    <meta property="og:description" content="Fluidigm Co. (NASDAQ:FLDM) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 1,460,000 shares, a decline of 8.8% from the September 30th total of 1,600,000 shares. Currently, 2.1% of the shares of the company are short sold. Based on an average daily volume of 914,300 shares, […]"/>
  </head>
  <body>
    <article>
      <h1>Fluidigm Co. (NASDAQ:FLDM) Sees Large Drop in Short Interest</h1>
      <address><time datetime="2019-11-19T10:26:00+00:00">19 Nov 2019, 10:26</time> by <a rel="author" href="https://www.thecerbatgem.com/author/teresa" target="_blank">Teresa Graham</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/fluidigm-co-logo.png"/>
      </figure>
      <p>Fluidigm Co. (NASDAQ:FLDM) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 1,460,000 shares, a decline of 8.8% from the September 30th total of 1,600,000 shares. Currently, 2.1% of the shares of the company are short sold. Based on an average daily volume of 914,300 shares, the short-interest ratio is presently 1.6 days.</p>
      <p>In related news, insider Levin Easterly Partners Llc sold 11,545 shares of Fluidigm stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $5.55, for a total transaction of $64,074.75. The transaction was disclosed in a filing with the SEC, which is available through <a href="https://www.sec.gov/Archives/edgar/data/1162194/000176615019000039/xslF345X03/primary_doc.xml">the SEC website</a>. 2.00% of the stock is currently owned by insiders.</p>
      <p>Institutional investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY acquired a new stake in Fluidigm during the 1st quarter valued at $151,000. FMR LLC acquired a new stake in Fluidigm during the 1st quarter valued at $24,188,000. First Quadrant L P CA grew its holdings in Fluidigm by 25.1% during the 2nd quarter. First Quadrant L P CA now owns 32,675 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 6,563 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Fluidigm during the 2nd quarter valued at $5,360,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Fluidigm during the 2nd quarter valued at $68,000. 97.13% of the stock is owned by institutional investors.</p>
      <p>Several equities research analysts have recently issued reports on the company. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> cut Fluidigm from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. BidaskClub raised Fluidigm from a “sell” rating to a “hold” rating in a research note on Saturday, November 2nd. UBS Group raised Fluidigm from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $14.00 to $7.00 in a research note on Friday, October 18th. Finally, Janney Montgomery Scott cut Fluidigm from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $10.81.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/FLDM/options/">NASDAQ FLDM</a> traded up $0.02 on Tuesday, hitting $2.35. The company’s stock had a trading volume of 2,398 shares, compared to its average volume of 1,277,989. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.89 and a quick ratio of 2.44. The company has a market capitalization of $174.61 million, a price-to-earnings ratio of -2.94 and a beta of 2.30. The stock has a 50 day moving average of $4.10 and a 200-day moving average of $8.34. Fluidigm has a 12-month low of $2.27 and a 12-month high of $14.90.</p>
      <p>Fluidigm (NASDAQ:FLDM) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. The business had revenue of $26.50 million for the quarter, compared to the consensus estimate of $28.74 million. Fluidigm had a negative net margin of 57.10% and a negative return on equity of 25.11%. The company’s quarterly revenue was down 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. Sell-side analysts expect that Fluidigm will post -0.6 EPS for the current fiscal year.</p>
      <p>
        <b>About Fluidigm</b>
      </p>
      <p>Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.</p>
      <p>Recommended Story: <a href="https://www.marketbeat.com/financial-terms/book-value-equity-per-share-bvps/">Book Value Of Equity Per Share – BVPS Explained</a></p>
    </article>
  </body>
</html>